X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/04/24/2869054/33525/en/FibroGen-Announces-Clinical-Data-from-Dose-Escalation-Phase-1b-Study-of-FG-3246-FOR46-in-Combination-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Can.html
https://www.prnewswire.com/news-releases/astellas-xtandi-enzalutamide-granted-european-commission-approval-for-use-in-additional-recurrent-early-prostate-cancer-treatment-setting-302124792.html
https://www.prnewswire.com/news-releases/astellas-receives-positive-chmp-opinion-for-xtandi-in-additional-recurrent-early-prostate-cancer-treatment-setting-302097043.html
https://www.prnewswire.com/news-releases/inside-information-made-public-nanoform-announces-important-milestone-with-promising-clinical-results-for-patient-centric-nanotechnology-enhanced-enzalutamide-302045594.html
https://www.prnewswire.com/news-releases/nanoform-commenced-relative-bioavailability-study-of-nanotechnology-enhanced-enzalutamide-302026984.html
https://www.prnewswire.com/news-releases/pfizer-and-astellas-xtandi-approved-by-us-fda-in-earlier-prostate-cancer-treatment-setting-301991574.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217920
https://www.prnewswire.com/news-releases/essa-pharma-announces-initiation-of-phase-2-study-evaluating-masofaniten-epi-7386-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-301929954.html
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-type-ii-variation-for-astellas-xtandi-enzalutamide-for-treatment-of-non-metastatic-hormone-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence-301925285.html
https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-xtandi-in-non-metastatic-castration-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence-301907279.html
https://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-hrr-gene-altered-mcrpc
https://www.fiercepharma.com/pharma/pfizer-astellas-build-case-xtandi-early-stage-hormone-sensitive-prostate-cancer
https://www.prnewswire.com/news-releases/xtandi-enzalutamide-plus-leuprolide-reduced-the-risk-of-metastasis-by-58-in-non-metastatic-hormone-sensitive-prostate-cancer-versus-placebo-plus-leuprolide-301811445.html
https://endpts.com/patients-appeal-nihs-rejection-to-use-march-in-rights-on-astellas-prostate-cancer-drug-xtandi/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-declines-force-lower-price-cancer-drug-xtandi-2023-03-21/
https://www.fiercepharma.com/pharma/astellas-pfizer-look-broaden-xtandis-patient-base-new-prostate-cancer-win-after-8-years
https://www.fiercepharma.com/pharma/pfizer-touts-xtandi-backbone-talzenna-parp-prostate-cancer-battle-astrazeneca-jj
https://www.merck.com/news/merck-announces-keynote-991-trial-evaluating-keytruda-pembrolizumab-plus-enzalutamide-and-androgen-deprivation-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-stop-for/
https://endpts.com/legislators-call-hhs-to-action-on-xtandi-march-in-rights/
https://www.prnewswire.com/news-releases/updated-results-from-the-phase-12-study-of-essas-lead-candidate-epi-7386-in-combination-with-enzalutamide-highlighted-at-the-29th-annual-prostate-cancer-foundation-scientific-retreat-301659500.html
https://www.globenewswire.com/news-release/2022/09/10/2513543/0/en/POINT-Biopharma-Provides-Updated-Efficacy-and-Safety-Data-from-the-Lead-In-Cohort-of-the-Phase-3-SPLASH-Trial-in-mCRPC-at-ESMO-Congress-2022.html
https://endpts.com/march-in-battles-heat-up-as-nonprofits-petition-hhs-on-6-drugs-even-as-earlier-petition-awaits-decision/
https://www.business-standard.com/article/companies/bdr-pharma-introduces-prostate-cancer-drug-with-enhanced-strength-122022801353_1.html
https://news.bloomberglaw.com/health-law-and-business/warren-urges-government-to-seize-patents-on-pfizers-cancer-drug?context=search&index=11
https://www.pharmaceutical-technology.com/news/us-fda-nuvation-bios-solid-tumour/
https://www.prnewswire.com/news-releases/essa-pharma-announces-first-patient-dosed-in-a-phase-12-clinical-trial-of-epi-7386-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-301463420.html
https://www.clinicaltrialsarena.com/news/astellas-pfizer-xtandi-prostate-cancer/
https://www.sharecast.com/news/market_reports/press-release-astellas-and-pfizers-xtandir-enzalutamide-reduced-risk-of-death-by-34-in-men-with-metastatic-hormone-sensitive-prostate-cancer-in-phase-3-arches-study--8103488.html
https://www.prnewswire.com/news-releases/astellas-and-pfizers-xtandi-enzalutamide-reduced-risk-of-death-by-34-in-men-with-metastatic-hormone-sensitive-prostate-cancer-in-phase-3-arches-study-301379604.html
https://www.raps.org/news-and-articles/news-articles/2021/8/fda-finalizes-guidance-on-metastasis-free-survival
https://www.fiercepharma.com/pharma/astellas-xtandi-nabs-leg-up-over-j-j-nice-prostate-cancer-win-uk
http://www.pharmatimes.com/news/astellas_xtandi_bags_nice_approval_in_prostate_cancer_1371455
https://www.prnewswire.com/news-releases/astellas-xtandi-enzalutamide-approved-by-european-commission-for-men-with-metastatic-hormone-sensitive-prostate-cancer-301282603.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209614
https://www.prnewswire.com/news-releases/astellas-receives-positive-chmp-opinion-for-xtandi-enzalutamide-for-patients-with-metastatic-hormone-sensitive-prostate-cancer-301256711.html
http://www.pharmatimes.com/news/astellas_xtandi_bags_additional_mhra_approval_in_prostate_cancer_1369816
http://www.pharmatimes.com/news/astellas_xtandi_bags_additional_mhra_approval_in_prostate_cancer_1369816
https://www.prnewswire.com/news-releases/astellas-receives-positive-chmp-opinion-for-xtandi-enzalutamide-for-patients-with-metastatic-hormone-sensitive-prostate-cancer-301256711.html
https://www.prnewswire.com/news-releases/essa-pharma-announces-clinical-collaboration-with-astellas-to-evaluate-the-combination-of-epi-7386-and-enzalutamide-for-patients-with-metastatic-castration-resistant-prostate-cancer-301235211.html
http://www.pharmafile.com/news/563272/china-approves-astellas-xtandi-non-metastatic-castration-resistant-prostate-cancer
https://www.prnewswire.com/news-releases/xtandi-enzalutamide-soft-capsules-approved-by-china-nmpa-for-the-treatment-of-non-metastatic-castration-resistant-prostate-cancer-301167743.html
https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/profound-overall-survival-data-with-olaparib-herald-practice-changing-treatment-metastatic-prostate-cancer
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharma-launches-80-mg-version-of-prostate-cancer-drug-at-rs-24480-per-pack-in-india/articleshow/78233398.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.globenewswire.com/news-release/2020/09/18/2095780/0/en/Veru-Announces-ESMO-Congress-2020-Oral-Presentation-of-Positive-Clinical-Results-from-its-VERU-111-Phase-1b-Study-in-Metastatic-Prostate-Cancer.html
https://www.news-medical.net/news/20200819/Enzalutamide-has-added-benefit-for-men-with-castration-resistant-prostate-cancer-at-high-risk-of-metastasis.aspx
Market Place
Share 
